Welcome to LookChem.com Sign In|Join Free

CAS

  • or
NORTRIPTYLINE, also known as Nortriptyline, is an organic tricyclic compound that serves as an active metabolite of amitriptyline. It is characterized by its relatively short latent period of action and is practically devoid of sedative effects. This makes it a suitable candidate for various psychiatric applications.

72-69-5 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 72-69-5 Structure
  • Basic information

    1. Product Name: NORTRIPTYLINE
    2. Synonyms: 5-(alpha-methylaminopropylidene)dibenzo[a,d]cyclohepta[1,4]diene;5-[3-(Methylamino)propylidene]dibenzo[a,E]cyclohepta[1,5]diene;5h-dibenzo(a,d)cycloheptene-delta(5,gamma)-propylamine,10,11-dihydro-n-methyl;5H-Dibenzo[a,d]cycloheptene-delta5,gamma-propylamine, 10,11-dihydro-N-methyl-;allegron;Amitryptyline, demethyl-;Ateben;Avantyl
    3. CAS NO:72-69-5
    4. Molecular Formula: C19H21N
    5. Molecular Weight: 263.38
    6. EINECS: 200-788-8
    7. Product Categories: N/A
    8. Mol File: 72-69-5.mol
  • Chemical Properties

    1. Melting Point: 58 °C
    2. Boiling Point: 396.62°C (rough estimate)
    3. Flash Point: 194.9 °C
    4. Appearance: /
    5. Density: 0.9790 (rough estimate)
    6. Vapor Pressure: 1.02E-06mmHg at 25°C
    7. Refractive Index: 1.4900 (estimate)
    8. Storage Temp.: N/A
    9. Solubility: N/A
    10. PKA: pKa 9.7 (Uncertain)
    11. CAS DataBase Reference: NORTRIPTYLINE(CAS DataBase Reference)
    12. NIST Chemistry Reference: NORTRIPTYLINE(72-69-5)
    13. EPA Substance Registry System: NORTRIPTYLINE(72-69-5)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 72-69-5(Hazardous Substances Data)

72-69-5 Usage

Uses

Used in Psychiatry:
NORTRIPTYLINE is used as an antidepressant for treating manic-depressive psychoses, endogenous depression, and major depressive conditions. Its effectiveness in these areas is attributed to its ability to alleviate symptoms and improve the overall mental health of patients.
Used in Pharmaceutical Industry:
NORTRIPTYLINE is used as an active ingredient in various pharmaceutical products, such as Aventyl Hydrochloride (Lilly), Aventyl Hydrochloride (Ranbaxy), and Pamelor (Tyco). These brand names represent the commercial availability of NORTRIPTYLINE in the market, providing patients with access to this potent antidepressant medication.

Originator

Aventyl,Lilly,UK,1963

Manufacturing Process

A mixture of 114.5 g of 5-(3-chloropropylidene)dibenzo[a,d]cyclohepta[1,4] diene, 75 ml of benzene, and about 400 ml of methylamine is heated in an autoclave at 120°C for six hours. The excess methylamine is distilled from the reaction mixture under vacuum and the residue is stirred with 300 ml of water. Acidification of the mixture with hydrochloric acid causes the separation of the hydrochloride of 5-(3-methylaminopropylidene)dibenzo[a,d] cyclohepta[1,4]diene. The product is collected by filtration and is purified by recrystallization from a mixture of absolute ethanol and ethyl acetate. MP 210°C to 212°C.

Therapeutic Function

Antidepressant

Clinical Use

Tricyclic antidepressant

Synthesis

Nortriptyline is 5-(3-methylaminopropyliden)-10,11-dihydrodibenzcycloheptene (7.1.17). Nortriptyline differs from desipramine in the same manner in which amitriptyline differs from imipramine. In nortriptyline, the nitrogen atom in the central part of the tricyclic system of desipramine is replaced by a carbon atom, which is bound to a side chain by a double bond. Two suggested methods of nortriptyline synthesis are based on the N-demethylation of amitriptyline. The third way utilizes the reaction of methylamine with 5-(3-bromopropyliden)-10,11-dihydro-5H-dibenz[a,d]cycloheptene (7.1.18). According to the first scheme, demethylation takes place by the reaction of amitriptyline (7.1.4) with methyliodide, which leads to the formation of a quaternary ammonium salt (7.1.16), the reaction of which with methylamine at a relatively high temperature gives the desired nortriptyline (7.1.17) [25]. According to the third scheme, nortriptyline is synthesized by reacting methylamine with 5-(3-bromopropyliden)-10,11-dihydro-5H-dibenz[a,d]cycloheptene (7.1.6) [8].

Drug interactions

Potentially hazardous interactions with other drugs Alcohol: increased sedative effect. Analgesics: increased risk of CNS toxicity with tramadol; possibly increased risk of side effects with nefopam; possibly increased sedative effects with opioids. Anti-arrhythmics: increased risk of ventricular arrhythmias with amiodarone - avoid; increased risk of ventricular arrhythmias with disopyramide, flecainide or propafenone; avoid with dronedarone. Antibacterials: increased risk of ventricular arrhythmias with delamanid, moxifloxacin and possibly telithromycin - avoid with moxifloxacin. Anticoagulants: may alter anticoagulant effect of coumarins. Antidepressants: enhanced CNS excitation and hypertension with MAOIs and moclobemide - avoid; concentration possibly increased with SSRIs; risk of ventricular arrhythmias with citalopram and escitalopram - avoid; increased risk of convulsions with vortioxetine. Antiepileptics: convulsive threshold lowered; concentration reduced by carbamazepine, fosphenytoin, phenobarbital and possibly phenytoin. Antimalarials: avoid with artemether/lumefantrine and piperaquine with artenimol. Antipsychotics: increased risk of ventricular arrhythmias especially with droperidol, haloperidol, pimozide, risperidone and sulpiride - avoid; increased antimuscarinic effects with clozapine and phenothiazines; concentration increased by antipsychotics. Antivirals: increased risk of ventricular arrhythmias with saquinavir - avoid; concentration possibly increased with ritonavir. Atomoxetine: increased risk of ventricular arrhythmias and possibly convulsions. Beta-blockers: increased risk of ventricular arrhythmias with sotalol. Clonidine: tricyclics antagonise hypotensive effect; increased risk of hypertension on clonidine withdrawal. Dapoxetine: possible increased risk of serotonergic effects - avoid. Dopaminergics: avoid use with entacapone; CNS toxicity reported with selegiline and rasagiline. Pentamidine: increased risk of ventricular arrhythmias. Sympathomimetics: increased risk of hypertension and arrhythmias with adrenaline and noradrenaline; metabolism possibly inhibited by methylphenidate.

Metabolism

Nortriptyline is a secondary amine dibenzocycloheptene TCA as well as the major metabolite of amitriptyline. Similar to desipramine, nortriptyline appears in mother's milk and is metabolized by CYP2D6 to the primary amine and by ring hydroxylation to its E-10-hydroxy metabolite. Approximately one-third of a dose of nortriptyline is excreted in urine as metabolites within 24 hours, and small amounts are excreted in feces via biliary elimination.

Check Digit Verification of cas no

The CAS Registry Mumber 72-69-5 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 7 and 2 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 72-69:
(4*7)+(3*2)+(2*6)+(1*9)=55
55 % 10 = 5
So 72-69-5 is a valid CAS Registry Number.
InChI:InChI=1/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-11,20H,6,12-14H2,1H3

72-69-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name nortriptyline

1.2 Other means of identification

Product number -
Other names allegron

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:72-69-5 SDS

72-69-5Synthetic route

amitriptyline hydrochloride
549-18-8

amitriptyline hydrochloride

A

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

B

10-Hydroxynortriptyline
1156-99-6

10-Hydroxynortriptyline

C

(Z)-10-Hydroxyamitriptyline
64520-05-4

(Z)-10-Hydroxyamitriptyline

Conditions
ConditionsYield
With glucose dehydrogenase; D-glucose; cytochrome P450BM3 F87A/H171L/Q307H/N319Y mutant; oxygen; β-nicotinamide adenine dinucleotide phosphate sodium salt In ethanol at 25℃; for 2h; pH=8.5; Enzymatic reaction;A 69%
B n/a
C n/a
N-methyl-4-(2-phenethylphenyl)but-3-yn-1-amine

N-methyl-4-(2-phenethylphenyl)but-3-yn-1-amine

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

Conditions
ConditionsYield
With trifluorormethanesulfonic acid In dichloromethane at 0℃; for 0.166667h; Friedel-Crafts Alkylation; regioselective reaction;68%
5-<3-(N-Carbethoxy-N-methyl-amino)-propyliden>-10,11-dihydro-dibenzocyclohepten
16234-88-1

5-<3-(N-Carbethoxy-N-methyl-amino)-propyliden>-10,11-dihydro-dibenzocyclohepten

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

Conditions
ConditionsYield
With potassium hydroxide In butan-1-ol at 120 - 125℃;
5-<3-(N-Methyl-p-toluolsulfonamido)-propyliden>-10,11-dihydro-dibenzocyclohepten
16235-12-4

5-<3-(N-Methyl-p-toluolsulfonamido)-propyliden>-10,11-dihydro-dibenzocyclohepten

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

Conditions
ConditionsYield
With hydrogen bromide; acetic acid; phenol
5-<3-(N-Carbethoxy-N-methyl-amino>-propyl>-10,11-dihydro-dibenzocyclohepten-5-ol
16234-89-2

5-<3-(N-Carbethoxy-N-methyl-amino>-propyl>-10,11-dihydro-dibenzocyclohepten-5-ol

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

Conditions
ConditionsYield
With hydrogen bromide In acetic acid Heating;
5-(3-bromo-1-propylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene
3436-04-2

5-(3-bromo-1-propylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene

methylamine
74-89-5

methylamine

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

Conditions
ConditionsYield
In benzene
In ethanol at 20℃; for 24h;
10,11-dihydro-5-[3-(methylamino)propyl]-5H-dibenzo[a,d]cyclohepten-5-ol
2939-66-4

10,11-dihydro-5-[3-(methylamino)propyl]-5H-dibenzo[a,d]cyclohepten-5-ol

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

Conditions
ConditionsYield
With toluene-4-sulfonic acid In toluene for 15h; Heating; Yield given;
Amitriptyline
50-48-6

Amitriptyline

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

Conditions
ConditionsYield
With oxygen; palladium on activated charcoal In methanol for 24h; Ambient temperature;
Multi-step reaction with 2 steps
1: benzene / Heating
2: KOH / butan-1-ol / 120 - 125 °C
View Scheme
Multi-step reaction with 2 steps
1: Py / Heating
2: HBr, AcOH, PhOH
View Scheme
With CYP2C19 Enzymatic reaction;
Multi-step reaction with 2 steps
1: triethylamine / 1,2-dichloro-ethane / 2 h / Reflux
2: 4 h / Reflux
View Scheme
Amitriptyline
50-48-6

Amitriptyline

A

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

B

(Z)-N,N-dimethyl-3-(10,11-dihydro-10-hydroxy-5H-dibenzocycloheptene)-Δ5,γ-propylamine
1159-82-6

(Z)-N,N-dimethyl-3-(10,11-dihydro-10-hydroxy-5H-dibenzocycloheptene)-Δ5,γ-propylamine

C

(-)-(E)-10-Hydroxy-Amitriptylline
64520-05-4, 129312-48-7, 129312-49-8

(-)-(E)-10-Hydroxy-Amitriptylline

Conditions
ConditionsYield
With glucose-6-phosphate dehydrogenase; Tris-HCl buffer; α-D-glucose 6-phosphate; liver microsomes of Wistar rats; NADPH; magnesium chloride In water at 37℃; Rate constant; Product distribution;
3-(5-Hydroxy-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-N-methyl-propionamide
115107-86-3

3-(5-Hydroxy-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-N-methyl-propionamide

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: LiAlH4 / tetrahydrofuran / 1.) reflux, 4 h, 2.) r.t., 15 h
2: p-TosOH / toluene / 15 h / Heating
View Scheme
3',4',10,11-Tetrahydro-spiro<5H-dibenzocyclohepten-5,5'(2'H)-furan>-2'-on
99082-15-2

3',4',10,11-Tetrahydro-spiro<5H-dibenzocyclohepten-5,5'(2'H)-furan>-2'-on

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: ethanol / 72 h / Ambient temperature
2: LiAlH4 / tetrahydrofuran / 1.) reflux, 4 h, 2.) r.t., 15 h
3: p-TosOH / toluene / 15 h / Heating
View Scheme
5-(3-bromo-1-propylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene
3436-04-2

5-(3-bromo-1-propylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 170 °C
2: HBr, AcOH, PhOH
View Scheme
5-(3-dimethylaminopropyl)-10,11-dihydrodibenzo[a,d]cyclohepten-5-ol
1159-03-1

5-(3-dimethylaminopropyl)-10,11-dihydrodibenzo[a,d]cyclohepten-5-ol

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: benzene / Heating
2: aq. HBr / acetic acid / Heating
View Scheme
2-[3-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidene)-propoxy]-tetrahydro-pyran

2-[3-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidene)-propoxy]-tetrahydro-pyran

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: aq. HBr / Heating
2: 170 °C
3: HBr, AcOH, PhOH
View Scheme
Multi-step reaction with 2 steps
1: aq. HBr / Heating
2: benzene
View Scheme
aminomethylfluorescein hydrochloride

aminomethylfluorescein hydrochloride

2-ethyl-5-phenylisoxazolium-3'-sulphonate
4156-16-5

2-ethyl-5-phenylisoxazolium-3'-sulphonate

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

Conditions
ConditionsYield
With triethylamine; trifluoroacetic acid In dichloromethane; N,N-dimethyl-formamide
Amitriptyline
50-48-6

Amitriptyline

A

hydroxy-amitriptyline

hydroxy-amitriptyline

B

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

C

Desmethylnortriptyline
4444-42-2

Desmethylnortriptyline

D

N,Ndimethyl-3-(10,11-dihydro-10-oxo-5H-dibenzocycloheptene)-Δ5,γ-propylamine
37401-47-1

N,Ndimethyl-3-(10,11-dihydro-10-oxo-5H-dibenzocycloheptene)-Δ5,γ-propylamine

Conditions
ConditionsYield
With NADPH In water; dimethyl sulfoxide at 37℃; for 1h; Microbiological reaction;
3-(10,11-dihydro-5H-dibenzocyclohepten-5-ylidene)propionitrile
40443-02-5

3-(10,11-dihydro-5H-dibenzocyclohepten-5-ylidene)propionitrile

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1.1: lithium aluminium tetrahydride / tetrahydrofuran
2.1: sodium hydride / mineral oil; N,N-dimethyl-formamide / 0.33 h
2.2: 4 h / 20 °C
View Scheme
Multi-step reaction with 2 steps
1.1: lithium aluminium tetrahydride / tetrahydrofuran / 1.33 h / Inert atmosphere; Cooling with ice
2.1: sodium hydride / N,N-dimethyl-formamide / 0.33 h / 0 °C
2.2: 4 h / 20 °C
View Scheme
Desmethylnortriptyline
4444-42-2

Desmethylnortriptyline

methyl iodide
74-88-4

methyl iodide

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

Conditions
ConditionsYield
Stage #1: Desmethylnortriptyline With sodium hydride In N,N-dimethyl-formamide; mineral oil for 0.333333h;
Stage #2: methyl iodide In N,N-dimethyl-formamide; mineral oil at 20℃; for 4h;
Stage #1: Desmethylnortriptyline With sodium hydride In N,N-dimethyl-formamide at 0℃; for 0.333333h;
Stage #2: methyl iodide In N,N-dimethyl-formamide at 20℃; for 4h;
5-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ol
55090-31-8

5-ethyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ol

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1.1: acetyl chloride / 1.5 h / Reflux
2.1: N-Bromosuccinimide; dibenzoyl peroxide / tetrachloromethane / 4 h / Reflux
3.1: acetone; water / 12 h / Reflux
4.1: lithium aluminium tetrahydride / tetrahydrofuran
5.1: sodium hydride / mineral oil; N,N-dimethyl-formamide / 0.33 h
5.2: 4 h / 20 °C
View Scheme
Multi-step reaction with 5 steps
1.1: acetyl chloride / 1.5 h / Reflux
2.1: N-Bromosuccinimide; dibenzoyl peroxide / tetrachloromethane / 4 h / Reflux
3.1: acetone; water / 12 h / Reflux
4.1: lithium aluminium tetrahydride / tetrahydrofuran / 1.33 h / Inert atmosphere; Cooling with ice
5.1: sodium hydride / N,N-dimethyl-formamide / 0.33 h / 0 °C
5.2: 4 h / 20 °C
View Scheme
5-Ethyliden-10,11-dihydro-5H-dibenzocycloheptan
28860-39-1

5-Ethyliden-10,11-dihydro-5H-dibenzocycloheptan

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1.1: N-Bromosuccinimide; dibenzoyl peroxide / tetrachloromethane / 4 h / Reflux
2.1: acetone; water / 12 h / Reflux
3.1: lithium aluminium tetrahydride / tetrahydrofuran
4.1: sodium hydride / mineral oil; N,N-dimethyl-formamide / 0.33 h
4.2: 4 h / 20 °C
View Scheme
Multi-step reaction with 4 steps
1.1: N-Bromosuccinimide; dibenzoyl peroxide / tetrachloromethane / 4 h / Reflux
2.1: acetone; water / 12 h / Reflux
3.1: lithium aluminium tetrahydride / tetrahydrofuran / 1.33 h / Inert atmosphere; Cooling with ice
4.1: sodium hydride / N,N-dimethyl-formamide / 0.33 h / 0 °C
4.2: 4 h / 20 °C
View Scheme
2-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)ethyl bromide
13099-16-6

2-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)ethyl bromide

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1.1: acetone; water / 12 h / Reflux
2.1: lithium aluminium tetrahydride / tetrahydrofuran
3.1: sodium hydride / mineral oil; N,N-dimethyl-formamide / 0.33 h
3.2: 4 h / 20 °C
View Scheme
Multi-step reaction with 3 steps
1.1: acetone; water / 12 h / Reflux
2.1: lithium aluminium tetrahydride / tetrahydrofuran / 1.33 h / Inert atmosphere; Cooling with ice
3.1: sodium hydride / N,N-dimethyl-formamide / 0.33 h / 0 °C
3.2: 4 h / 20 °C
View Scheme
C19H20O3S

C19H20O3S

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: ethanol; water / 2 h / 50 °C
2: trifluorormethanesulfonic acid / dichloromethane / 0.17 h / 0 °C
View Scheme
1-Bromo-2-iodobenzene
583-55-1

1-Bromo-2-iodobenzene

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1: bis-triphenylphosphine-palladium(II) chloride; triethylamine; copper(l) iodide / acetonitrile / 22 h / 0 - 20 °C
2: hydrogen; palladium 10% on activated carbon / ethyl acetate / 6 h / 20 °C
3: caesium carbonate; dichloro bis(acetonitrile) palladium(II); dicyclohexyl-(2',6'-dimethoxybiphenyl-2-yl)-phosphane / acetonitrile / 6.5 h / 60 °C
4: triethylamine / dichloromethane / 2.5 h / 0 °C
5: ethanol; water / 2 h / 50 °C
6: trifluorormethanesulfonic acid / dichloromethane / 0.17 h / 0 °C
View Scheme
1-bromo-2-(phenylethenyl)benzene
21375-88-2

1-bromo-2-(phenylethenyl)benzene

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: hydrogen; palladium 10% on activated carbon / ethyl acetate / 6 h / 20 °C
2: caesium carbonate; dichloro bis(acetonitrile) palladium(II); dicyclohexyl-(2',6'-dimethoxybiphenyl-2-yl)-phosphane / acetonitrile / 6.5 h / 60 °C
3: triethylamine / dichloromethane / 2.5 h / 0 °C
4: ethanol; water / 2 h / 50 °C
5: trifluorormethanesulfonic acid / dichloromethane / 0.17 h / 0 °C
View Scheme
1-(2-bromophenyl)-2-phenylethane
57918-64-6

1-(2-bromophenyl)-2-phenylethane

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: caesium carbonate; dichloro bis(acetonitrile) palladium(II); dicyclohexyl-(2',6'-dimethoxybiphenyl-2-yl)-phosphane / acetonitrile / 6.5 h / 60 °C
2: triethylamine / dichloromethane / 2.5 h / 0 °C
3: ethanol; water / 2 h / 50 °C
4: trifluorormethanesulfonic acid / dichloromethane / 0.17 h / 0 °C
View Scheme
4-(2-phenethylphenyl)but-3-yn-1-ol

4-(2-phenethylphenyl)but-3-yn-1-ol

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: triethylamine / dichloromethane / 2.5 h / 0 °C
2: ethanol; water / 2 h / 50 °C
3: trifluorormethanesulfonic acid / dichloromethane / 0.17 h / 0 °C
View Scheme
phenylacetylene
536-74-3

phenylacetylene

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1: bis-triphenylphosphine-palladium(II) chloride; triethylamine; copper(l) iodide / acetonitrile / 22 h / 0 - 20 °C
2: hydrogen; palladium 10% on activated carbon / ethyl acetate / 6 h / 20 °C
3: caesium carbonate; dichloro bis(acetonitrile) palladium(II); dicyclohexyl-(2',6'-dimethoxybiphenyl-2-yl)-phosphane / acetonitrile / 6.5 h / 60 °C
4: triethylamine / dichloromethane / 2.5 h / 0 °C
5: ethanol; water / 2 h / 50 °C
6: trifluorormethanesulfonic acid / dichloromethane / 0.17 h / 0 °C
View Scheme
10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-one
1210-35-1

10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-one

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1.1: diethyl ether / 1.25 h / 20 °C / Reflux
2.1: acetyl chloride / 1.5 h / Reflux
3.1: N-Bromosuccinimide; dibenzoyl peroxide / tetrachloromethane / 4 h / Reflux
4.1: acetone; water / 12 h / Reflux
5.1: lithium aluminium tetrahydride / tetrahydrofuran / 1.33 h / Inert atmosphere; Cooling with ice
6.1: sodium hydride / N,N-dimethyl-formamide / 0.33 h / 0 °C
6.2: 4 h / 20 °C
View Scheme
amitriptyline hydrochloride
549-18-8

amitriptyline hydrochloride

A

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

B

(Z)-10-Hydroxyamitriptyline
64520-05-4

(Z)-10-Hydroxyamitriptyline

Conditions
ConditionsYield
With glucose dehydrogenase; D-glucose; cytochrome P450BM3 R47L/Y51F/V78I/A191T/N239H/I259V/A276T/A330P/L353I mutant; oxygen; β-nicotinamide adenine dinucleotide phosphate sodium salt In ethanol at 25℃; for 2h; pH=8.5; Enzymatic reaction;A n/a
B 18.7 mg
3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

carbon dioxide
1111-72-4

carbon dioxide

[N-13CH3]-amitriptyline

[N-13CH3]-amitriptyline

Conditions
ConditionsYield
With hydrogen; tris(acetylacetonato)ruthenium(III); lithium chloride; [2-((diphenylphospino)methyl)-2-methyl-1,3-propanediyl]bis[diphenylphosphine] In tetrahydrofuran at 140℃; for 20h; Autoclave; Inert atmosphere;96%
3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

ethyl acrylate
140-88-5

ethyl acrylate

3-{[3-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-methyl-amino}-propionic acid ethyl ester

3-{[3-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-methyl-amino}-propionic acid ethyl ester

Conditions
ConditionsYield
In ethanol for 2h; Heating;95%
3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

trifluoroacetic acid
76-05-1

trifluoroacetic acid

3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N-methyl-N-(2,2,2-trifluoroethyl)propan-1-amine

3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N-methyl-N-(2,2,2-trifluoroethyl)propan-1-amine

Conditions
ConditionsYield
With potassium phosphate; 18-crown-6 ether; phenylsilane In tetrahydrofuran at 80℃; for 4h; Glovebox; Molecular sieve; Schlenk technique;94%
silver(I) trifluoromethoxide
1006904-72-8

silver(I) trifluoromethoxide

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

(3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)propyl)(methyl)carbamic fluoride

(3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)propyl)(methyl)carbamic fluoride

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In acetonitrile at 20℃; for 2h; Inert atmosphere;93%
3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

Bromodiphenylmethane
776-74-9

Bromodiphenylmethane

N-benzhydryl-3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N-methylpropan-1-amine

N-benzhydryl-3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N-methylpropan-1-amine

Conditions
ConditionsYield
With triethylamine In acetonitrile at 100℃; for 12h; Inert atmosphere;91%
α-bromo-γ-butyrolactone
5061-21-2

α-bromo-γ-butyrolactone

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

3-[methyl(3-{tricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14- hexaen-2-ylidene}propyl)amino]oxolan-2-one

3-[methyl(3-{tricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14- hexaen-2-ylidene}propyl)amino]oxolan-2-one

Conditions
ConditionsYield
With tetrabutylammomium bromide; potassium carbonate In acetonitrile at 0 - 20℃;89%
carbon dioxide
124-38-9

carbon dioxide

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

ethyl iodide
75-03-6

ethyl iodide

5-<3-(N-Carbethoxy-N-methyl-amino)-propyliden>-10,11-dihydro-dibenzocyclohepten
16234-88-1

5-<3-(N-Carbethoxy-N-methyl-amino)-propyliden>-10,11-dihydro-dibenzocyclohepten

Conditions
ConditionsYield
With caesium carbonate In dimethyl sulfoxide at 20℃; chemoselective reaction;86%
3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

1-((3,5-difluorophenyl)sulfonyl)bicyclo[1.1.0]butane

1-((3,5-difluorophenyl)sulfonyl)bicyclo[1.1.0]butane

C23H27N

C23H27N

Conditions
ConditionsYield
Stage #1: 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine; 1-((3,5-difluorophenyl)sulfonyl)bicyclo[1.1.0]butane In dimethyl sulfoxide at 20℃; for 24h; Sonication;
Stage #2: With magnesium In deuteromethanol
83%
3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

2-iodo-4,N-dimethyl-N-phenylethynylbenzenesulfonamide

2-iodo-4,N-dimethyl-N-phenylethynylbenzenesulfonamide

C35H34N2O2S

C35H34N2O2S

Conditions
ConditionsYield
With bis-triphenylphosphine-palladium(II) chloride; potassium carbonate In dimethyl sulfoxide at 70℃; for 12h; Schlenk technique; Inert atmosphere; Sealed tube;76%
carbon dioxide
124-38-9

carbon dioxide

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

N-(3-(10,11-dihydro-5H-dibenso[a,d][7]annulen-5-ylidene)propyl)-N-methylformamide

N-(3-(10,11-dihydro-5H-dibenso[a,d][7]annulen-5-ylidene)propyl)-N-methylformamide

Conditions
ConditionsYield
With phenylsilane; tetrabutyl ammonium fluoride at 20℃; for 4h;70%
3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

2-bromo-N-(4-chlorobenzyl)-4-(1,3-dioxoisoindolin-2-yl)butanamide
1621341-90-9

2-bromo-N-(4-chlorobenzyl)-4-(1,3-dioxoisoindolin-2-yl)butanamide

N-[(4-chlorophenyl)methyl]-4-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-2-[methyl(3-{tricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-2-ylidene}propyl)amino]butanamide

N-[(4-chlorophenyl)methyl]-4-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-2-[methyl(3-{tricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-2-ylidene}propyl)amino]butanamide

Conditions
ConditionsYield
With potassium carbonate In acetonitrile for 24h; Reflux;64%
carbon dioxide
124-38-9

carbon dioxide

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

Amitriptyline
50-48-6

Amitriptyline

Conditions
ConditionsYield
With diphenylsilane; [1,3-bis(2,4,6-trimethylphenyl)imidazol]-2-ylidene In N,N-dimethyl-formamide at 50℃; under 760.051 Torr; chemoselective reaction;63%
With hydrogen; tris(acetylacetonato)ruthenium(III); lithium chloride; [2-((diphenylphospino)methyl)-2-methyl-1,3-propanediyl]bis[diphenylphosphine] In tetrahydrofuran at 140℃; for 24h; Autoclave; Inert atmosphere;81 %Chromat.
3-chlorothiophene-2-carboxylic acid
59337-89-2

3-chlorothiophene-2-carboxylic acid

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

3-chloro-N-[3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)propyl]-N-methylthiophene-2-carboxamide
1067431-34-8

3-chloro-N-[3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)propyl]-N-methylthiophene-2-carboxamide

Conditions
ConditionsYield
With benzotriazol-1-ol; N-(3-dimethylaminopropyl)-N-ethylcarbodiimide; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 16h;56%
3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

1-oxyl-2,2,5,5-tetramethylpyrrolidinyl-3-carboxylic acid N-hydroxysuccinimide ester
58537-73-8

1-oxyl-2,2,5,5-tetramethylpyrrolidinyl-3-carboxylic acid N-hydroxysuccinimide ester

A

C28H35N2O2

C28H35N2O2

B

C32H40N3O5

C32H40N3O5

Conditions
ConditionsYield
In tetrahydrofuran 1) 4d, RT, 2) 50-60 deg C, 3 d;A 55%
B 29%
3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

[1,4]naphthoquinone
130-15-4

[1,4]naphthoquinone

2-cyclohepten-5-yliden)-propylamino>-1,4-naphthochinon

2-cyclohepten-5-yliden)-propylamino>-1,4-naphthochinon

Conditions
ConditionsYield
In dichloromethane for 1h; Ambient temperature; in the dark;54%
N-benzyl-2-bromo-4-(1,3-dioxoisoindolin-2-yl)butanamide
16699-70-0

N-benzyl-2-bromo-4-(1,3-dioxoisoindolin-2-yl)butanamide

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

N-benzyl-4-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-2-[methyl(3-{tricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-2-ylidene}propyl)amino]butanamide

N-benzyl-4-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-2-[methyl(3-{tricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-2-ylidene}propyl)amino]butanamide

Conditions
ConditionsYield
With potassium carbonate In acetonitrile for 24h; Reflux;52%
3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

2-Methyl-1,4-benzoquinone
553-97-9

2-Methyl-1,4-benzoquinone

A

5-Methyl-2-cyclohepten-5-yliden)-propylamino>-1,4-benzochinon
108141-74-8

5-Methyl-2-cyclohepten-5-yliden)-propylamino>-1,4-benzochinon

B

6-Methyl-2-cyclohepten-5-yliden)-propylamino>-1,4-benzochinon
108141-78-2

6-Methyl-2-cyclohepten-5-yliden)-propylamino>-1,4-benzochinon

Conditions
ConditionsYield
In dichloromethane for 24h; Ambient temperature;A 51%
B 34%
3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

6-O-trityl-D-glucopyranose
54325-28-9

6-O-trityl-D-glucopyranose

A

N-[6-O-trityl-D-glucopyranosyl]-N-methyl-3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propanamine

N-[6-O-trityl-D-glucopyranosyl]-N-methyl-3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propanamine

B

N-[6-O-trityl-β-D-glucopyranosyl]-N-methyl-3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propanamine
1186033-19-1

N-[6-O-trityl-β-D-glucopyranosyl]-N-methyl-3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propanamine

Conditions
ConditionsYield
In dichloromethane at 20℃; Inert atmosphere;A n/a
B 49%
2,3-Dichloro-1,4-naphthoquinone
117-80-6

2,3-Dichloro-1,4-naphthoquinone

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

3-Chlor-2-cyclohepten-5-yliden)-propylamino>-1,4-naphthochinon

3-Chlor-2-cyclohepten-5-yliden)-propylamino>-1,4-naphthochinon

Conditions
ConditionsYield
In dichloromethane for 2h;48%
3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

2-bromo-N-(2-chlorobenzyl)-4-(1,3-dioxoisoindolin-2-yl)butanamide
1621341-88-5

2-bromo-N-(2-chlorobenzyl)-4-(1,3-dioxoisoindolin-2-yl)butanamide

N-[(2-chlorophenyl)methyl]-4-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-2-[methyl(3-{tricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-2-ylidene}propyl)amino]butanamide

N-[(2-chlorophenyl)methyl]-4-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-2-[methyl(3-{tricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-2-ylidene}propyl)amino]butanamide

Conditions
ConditionsYield
With potassium carbonate In acetonitrile for 24h; Reflux;47%
3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

2-bromo-4-(1,3-dioxoisoindolin-2-yl)-N-(4-fluorobenzyl)butanamide
1621341-92-1

2-bromo-4-(1,3-dioxoisoindolin-2-yl)-N-(4-fluorobenzyl)butanamide

N-[(4-fluorophenyl)methyl]-4-(1,3-dioxo-2,3-dihydro-1Hisoindol-2-yl)-2-[methyl(3-{tricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-2-ylidene}propyl)amino]butanamide

N-[(4-fluorophenyl)methyl]-4-(1,3-dioxo-2,3-dihydro-1Hisoindol-2-yl)-2-[methyl(3-{tricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-2-ylidene}propyl)amino]butanamide

Conditions
ConditionsYield
With potassium carbonate In acetonitrile for 24h; Reflux;47%
3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

2-bromo-4-(1,3-dioxoisoindolin-2-yl)-N-(4-methylbenzyl)butanamide
1621341-94-3

2-bromo-4-(1,3-dioxoisoindolin-2-yl)-N-(4-methylbenzyl)butanamide

4-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-2-[methyl(3-{tricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-2-ylidene}propyl)amino]-N-[(4-methylphenyl)methyl]butanamide

4-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)-2-[methyl(3-{tricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-2-ylidene}propyl)amino]-N-[(4-methylphenyl)methyl]butanamide

Conditions
ConditionsYield
With potassium carbonate In acetonitrile for 24h; Reflux;45%
3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

N-Methyl-3-(10,11-dihydro-5H-dibenzocyclohepten-5-yliden)-propylamino-1,4-benzochinon

N-Methyl-3-(10,11-dihydro-5H-dibenzocyclohepten-5-yliden)-propylamino-1,4-benzochinon

2,5-Bis-cyclohepten-5-yliden)-propylamino>-1,4-benzochinon

2,5-Bis-cyclohepten-5-yliden)-propylamino>-1,4-benzochinon

Conditions
ConditionsYield
In dichloromethane Ambient temperature;44%
3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

2,3-Dibromo-1,4-naphthoquinone
13243-65-7

2,3-Dibromo-1,4-naphthoquinone

3-Brom-2-cyclohepten-5-yliden)-propylamino>-1,4-naphthochinon

3-Brom-2-cyclohepten-5-yliden)-propylamino>-1,4-naphthochinon

Conditions
ConditionsYield
In dichloromethane for 1h;42%
3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

1-(2-Chloroethyl)-4-methoxybenzene
18217-00-0

1-(2-Chloroethyl)-4-methoxybenzene

3-(5,6-dihydrodibenzo[2,1-b:1',2'-e][7]annulen-11-ylidene)-N-[2-(4-methoxyphenyl)ethyl]-N-methylpropan-1-amine

3-(5,6-dihydrodibenzo[2,1-b:1',2'-e][7]annulen-11-ylidene)-N-[2-(4-methoxyphenyl)ethyl]-N-methylpropan-1-amine

Conditions
ConditionsYield
Stage #1: 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine With n-butyllithium In tetrahydrofuran; hexane at -78℃; for 1h; Inert atmosphere;
Stage #2: 1-(2-Chloroethyl)-4-methoxybenzene With triisobutylaluminum In tetrahydrofuran; hexane; toluene for 48h; Reflux; Inert atmosphere;
31%
2-(3,4-dimethoxyphenyl)-ethylchloride
27160-08-3

2-(3,4-dimethoxyphenyl)-ethylchloride

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

3-(5,6-dihydrodibenzo[2,1-b:1',2'-e][7]annulen-11-ylidene)-N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methylpropan-1-amine

3-(5,6-dihydrodibenzo[2,1-b:1',2'-e][7]annulen-11-ylidene)-N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methylpropan-1-amine

Conditions
ConditionsYield
Stage #1: 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine With n-butyllithium In tetrahydrofuran; hexane at -78℃; for 1h; Inert atmosphere;
Stage #2: 2-(3,4-dimethoxyphenyl)-ethylchloride With triisobutylaluminum In tetrahydrofuran; hexane; toluene for 48h; Reflux; Inert atmosphere;
27%
3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
72-69-5

3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine

1-bromo-2,3,4-tri-O-acetyl-α-D-glucuronic acid methyl ester
21085-72-3

1-bromo-2,3,4-tri-O-acetyl-α-D-glucuronic acid methyl ester

A

methyl 2-acetoxy-3,4-di-O-acetyl-D-arabino-hex-1-enopyranuronate
62346-09-2

methyl 2-acetoxy-3,4-di-O-acetyl-D-arabino-hex-1-enopyranuronate

B

C32H37NO9
1207167-91-6

C32H37NO9

Conditions
ConditionsYield
With sodium carbonate In dichloromethane; water; acetoneA n/a
B 26%

72-69-5Relevant articles and documents

Development of tricyclic N-benzyl-4-hydroxybutanamide derivatives as inhibitors of GABA transporters mGAT1-4 with anticonvulsant, antinociceptive, and antidepressant activity

Bajda, Marek,Filipek, Barbara,Kotniewicz, Krzysztof,Kulig, Katarzyna,Latacz, Gniewomir,Maj, Maciej,Malawska, Barbara,Podkowa, Adrian,Rapacz, Anna,Wanner, Klaus T.,??tka, Kamil,H?fner, Georg C.,Jó?wiak, Krzysztof,Sa?at, Kinga,Zar?ba, Paula

, (2021/05/26)

γ-Aminobutyric acid (GABA) neurotransmission has a significant impact on the proper functioning of the central nervous system. Numerous studies have indicated that inhibitors of the GABA transporters mGAT1-4 offer a promising strategy for the treatment of several neurological disorders, including epilepsy, neuropathic pain, and depression. Following our previous results, herein, we report the synthesis, biological evaluation, and structure-activity relationship studies supported by molecular docking and molecular dynamics of a new series of N-benzyl-4-hydroxybutanamide derivatives regarding their inhibitory potency toward mGAT1-4. This study allowed us to identify compound 23a (N-benzyl-4-hydroxybutanamide bearing a dibenzocycloheptatriene moiety), a nonselective GAT inhibitor with a slight preference toward mGAT4 (pIC50 = 5.02 ± 0.11), and compound 24e (4-hydroxy-N-[(4-methylphenyl)-methyl]butanamide bearing a dibenzocycloheptadiene moiety) with relatively high inhibitory activity toward mGAT2 (pIC50 = 5.34 ± 0.09). In a set of in vivo experiments, compound 24e successively showed predominant anticonvulsant activity and antinociception in the formalin model of tonic pain. In contrast, compound 23a showed significant antidepressant-like properties in mice. These results were consistent with the available literature data, which indicates that, apart from seizure control, GABAergic neurotransmission is also involved in the pathophysiology of several psychiatric diseases, however alternative mechanisms underlying this action cannot be excluded. Finally, it is worth noting that the selected compounds showed unimpaired locomotor skills that have been indicated to give reliable results in behavioral assays.

NB 06: From a simple lysosomotropic aSMase inhibitor to tools for elucidating the role of lysosomes in signaling apoptosis and LPS-induced inflammation

Blaess, Markus,Bibak, Nelly,Claus, Ralf A.,Kohl, Matthias,Bonaterra, Gabriel A.,Kinscherf, Ralf,Laufer, Stefan,Deigner, Hans-Peter

, p. 73 - 104 (2017/10/17)

Ceramide generation is involved in signal transduction of cellular stress response, in particular during stress-induced apoptosis in response to stimuli such as minimally modified Low-density lipoproteins, TNFalpha and exogenous C6-ceramide. In this paper we describe 48 diverse synthetic products and evaluate their lysosomotropic and acid sphingomyelinase inhibiting activities in macrophages. A stimuli-induced increase of C16-ceramide in macrophages can be almost completely suppressed by representative compound NB 06 providing an effective protection of macrophages against apoptosis. Compounds like NB 06 thus offer highly interesting fields of application besides prevention of apoptosis of macrophages in atherosclerotic plaques in vessel walls. Most importantly, they can be used for blocking pH-dependent lysosomal processes and enzymes in general as well as for analyzing lysosomal dependent cellular signaling. Modulation of gene expression of several prominent inflammatory messengers IL1B, IL6, IL23A, CCL4 and CCL20 further indicate potentially beneficial effects in the field of (systemic) infections involving bacterial endotoxins like LPS or infections with influenza A virus.

A novel strategy for spectrophotometric simultaneous determination of amitriptyline and nortriptyline based on derivation with a quinonoid compound in serum samples

Farnoudian-Habibi, Amir,Massoumi, Bakhshali,Jaymand, Mehdi

, p. 235 - 243 (2016/07/06)

A novel and efficient strategy for the simultaneous determination of two tricyclic antidepressant (TCA) drugs [amitriptyline (AT), and its main metabolite (nortriptyline; NT)] via a combination of magnetic solid phase extraction (MSPE), and spectrophotometric techniques in serum is suggested. For this purpose, the imidazolium ionic liquid (Imz)-modified Fe3O4@SiO2 nanoparticles (Fe3O4@SiO2-Imz) was employed as an adsorbent for theMSPE. Preconcentration (loadingdesorption) studies were performed under optimized conditions including pH, adsorbent amount, contact time, eluent volume, and desorption time. Afterward, determination of each drug was carried out by specific strategy. Acetaldehyde (AC), and 2,3,5,6-tetrachloro-1,4-benzoquinone (chloranil; CL) were used as chemical reagents for reaction with NT, while AT did not react with these reagents. This method is based on the condensation reaction between secondary amine group of NT and AC to afford an enamine, and subsequently reaction with CL to produce a chlorinated quinone-substituted enamine. The final product exhibited maximum absorption at 556 nm, while the AT was determined at 240 nm. The limits of detections (LODs) for NT and AT in serum sample were obtained as 0.19 and 0.90 ng mL-1, respectively. The limits of quantifications (LOQs) were obtained to be 0.63 and 2.93 ng mL-1 for NT and AT, respectively. A linear range was obtained to be 1 to 5 ng mL-1. Results indicated that the suggested method is applicable for simultaneous determination of NT and AT in serum samples.

Drug Oxidation by Cytochrome P450BM3: Metabolite Synthesis and Discovering New P450 Reaction Types

Ren, Xinkun,Yorke, Jake A.,Taylor, Emily,Zhang, Ting,Zhou, Weihong,Wong, Luet Lok

, p. 15039 - 15047 (2015/10/20)

There is intense interest in late-stage catalytic C-H bond functionalization as an integral part of synthesis. Effective catalysts must have a broad substrate range and tolerate diverse functional groups. Drug molecules provide a good test of these attributes of a catalyst. A library of P450BM3 mutants developed from four base mutants with high activity for hydrocarbon oxidation produced human metabolites of a panel of drugs that included neutral (chlorzoxazone, testosterone), cationic (amitriptyline, lidocaine) and anionic (diclofenac, naproxen) compounds. No single mutant was active for all the tested drugs but multiple variants in the library showed high activity with each compound. The high conversions enabled full product characterization that led to the discovery of the new P450 reaction type of oxidative decarboxylation of an α-hydroxy carboxylic acid and the formation a protected imine from an amine, offering a novel route to α-functionalization of amines. The substrate range and varied product profiles suggest that this library of enzymes is a good basis for developing late-stage C-H activation catalysts.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES

-

, (2015/05/26)

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of depressive disorders, anxiety disorders, attention deficit hyperactivity disorder, migraine prophylaxis, eating disorders, bipolar disorder, post-herpetic neuralgia, insomnia, ankylosing spondylitis, recurring biliary dyskinesia, nocturnal enuresis, cyclic vomiting syndrome, post-traumatic stress disorder (PTSD) and neuropathy.

Construction of dibenzo-fused seven- to nine-membered carbocycles via Bronsted acid-promoted intramolecular Friedel - Crafts-type alkenylation

Otani, Takashi,Ueki, Kanako,Cho, Kinryo,Kanai, Kan,Tateno, Kotaro,Saito, Takao

, p. 7895 - 7898 (2015/05/13)

Bronsted acid-promoted intramolecular hydroarylation of alkynylbenzenes carrying an arylalkyl group at the ortho-position leads to alkylidenedibenzo[a,d]cycloheptenes, -octenes and -nonenes in up to quantitative yield with complete regioselectivity. The scope and limitation of this reaction and application to the synthesis of tricyclic antidepressants are described.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES

-

, (2013/12/03)

The invention relates to the compounds of formula (I) or its pharmaceutica! acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula (I), and methods for the treatment of neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of depressive disorders, anxiety disorders, attention deficit hyperactivity disorder, migraine prophylaxis, eating disorders, bipolar disorder, post-herpetic neuralgia, insomnia, ankylosing spondylitis, recurring biliary dyskinesia, nocturnal enuresis, cyclic vomiting syndrome, post-traumatic stress disorder (PTSD) and neuropathy.

Comparison of triple quadrupole, hybrid linear ion trap triple quadrupole, time-of-flight and LTQ-orbitrap mass spectrometers in drug discovery phase metabolite screening and identification in vitro - amitriptyline and verapamil as model compounds

Rousu, Timo,Herttuainen, Jukka,Tolonen, Ari

experimental part, p. 939 - 957 (2011/10/19)

Liquid chromatography in combination with mass spectrometry (LC/MS) is a superior analytical technique for metabolite profiling and identification studies performed in drug discovery and development laboratories. In the early phase of drug discovery the analytical approach should be both time- and cost-effective, thus providing as much data as possible with only one visit to the laboratory, without the need for further experiments. Recent developments in mass spectrometers have created a situation where many different mass spectrometers are available for the task, each with their specific strengths and drawbacks. We compared the metabolite screening properties of four main types of mass spectrometers used in analytical laboratories, considering both the ability to detect the metabolites and provide structural information, as well as the issues related to time consumption in laboratory and thereafter in data processing. Human liver microsomal incubations with amitriptyline and verapamil were used as test samples, and early-phase 'one lab visit only' approaches were used with all instruments. In total, 28 amitriptyline and 69 verapamil metabolites were found and tentatively identified. Time-of-flight mass spectrometry (TOFMS) was the only approach detecting all of them, shown to be the most suitable instrument for elucidating as comprehensive metabolite profile as possible leading also to lowest overall time consumption together with the LTQ-Orbitrap approach. The latter however suffered from lower detection sensitivity and false negatives, and due to slow data acquisition rate required slower chromatography. Approaches with triple quadrupole mass spectrometry (QqQ) and hybrid linear ion trap triple quadrupole mass spectrometry (Q-Trap) provided the highest amount of fragment ion data for structural elucidation, but, in addition to being unable to produce very high-important accurate mass data, they suffered from many false negatives, and especially with the QqQ, from very high overall time consumption.

PAINKILLING ASSOCIATION COMPRISING A DIHYDROIMIDAZOPYRAZINE DERIVATIVE

-

, (2009/10/31)

The invention relates to a product comprising (1R)-1-[(({2R)-2-amino-3-[(8S)-8-(cyclohexylmethyl) -2-phenyl-5,6-dihydroimidazo [1,2-a]pyrazin-7(8H)-yl]-3-oxopropyl}dithio)methyl]-2-[(8S)-8-(cyclohexylmethyl) -2-phenyl-5,6-dihydrolmidazo[1,2-a]pyrazin-7(8H)-yl]-2-oxoethylamine in association with an analgesic agent selected from morphine, the similar or a morphine derivative, sodium channel inhibitors, non-steroidal antiflammatory agents (AINS), glutamatergic system inhibitors, tricycle antidepressants and gabaergic derivatives for simultaneous therapeutic use which is separated or out over the time for pain treatment or prevention.

Reagents and methods for the quantification of amitriptyline or nortriptyline in biological fluids

-

, (2008/06/13)

Immunoassay methods and reagents for the specific quantification of amitriptyline or nortriptyline in a test sample are disclosed employing antibodies prepared with amitriptyline or nortriptyline derivatives of the Formula III: STR1 wherein for amitriptyline, R is CH3, and for nortriptyline, R is H. The present invention also describes the synthesis of unique fluorescein tracers of the structure of Formula IV and Formula V: STR2 wherein for a specific amitriptyline immunoassay, W1 is a heteroatom linked to the aromatic ring at the 2 or 3 position, and for a specific nortriptyline immunoassay, W2 is two heteroatoms linked together and attached to the aromatic ring at the 2 or 3 position, and wherein Q is a detectable moiety, preferably fluorescein or a fluorescein derivative.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 72-69-5